Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes
Intravitreal Ranibizumab (Lucentis) monotherapy is currently the standard of care for neovascular age-related macular degeneration (AMD), supported by well-conducted clinical trials and non-randomised studies. 1-4 Visual and anatomical outcomes are definitely better than Verteporfin Photodynamic the...
Gespeichert in:
| Veröffentlicht in: | British journal of ophthalmology 2010-11, Vol.94 (11), p.1543-1545 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1545 |
|---|---|
| container_issue | 11 |
| container_start_page | 1543 |
| container_title | British journal of ophthalmology |
| container_volume | 94 |
| creator | Raja, M S A Saldana, M Goldsmith, C Burton, B J L |
| description | Intravitreal Ranibizumab (Lucentis) monotherapy is currently the standard of care for neovascular age-related macular degeneration (AMD), supported by well-conducted clinical trials and non-randomised studies. 1-4 Visual and anatomical outcomes are definitely better than Verteporfin Photodynamic therapy (PDT), but the treatment comes at a cost. 5 The current goal of anti-vascular endothelial growth factor (VEGF) agents is to stabilise and/or improve vision. |
| doi_str_mv | 10.1136/bjo.2009.174763 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_759875519</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>759875519</sourcerecordid><originalsourceid>FETCH-LOGICAL-b397t-8db4d3740c33cc5303757047c57ea5d1c6e8fd447a53e5e63a992e32b91db3c43</originalsourceid><addsrcrecordid>eNqFkUtv1DAURiMEokNhzQ5ZYsFDyowfiR2zQ6NCkUZFQgUkNpbt3Jl6SOzBdlrKP-Hf4iqlCzasbF-f7_pxquopwUtCGF-ZfVhSjOWSiEZwdq9akIZ3NcVC3q8WGGNRE8LJUfUopX1ZUk7Ew-qI4rZUG7qofn_S3hn3axq1QTmCziP4jLYhIg_hUic7DToivYM6wqAz9GjUc62HHXiIOrvgkfPoUGYlm9CVyxdoF0KPjE4wOA_o0qVJD6gkXb5GLw3kDBHlC-0RXxH66g0itB6DL8EwZRtGSI-rB1s9JHhyOx5Xn9-dnK9P683H9x_Wbze1YVLkuutN0zPRYMuYtS3DTLQCN8K2AnTbE8uh2_ZNI3TLoAXOtJQUGDWS9IbZhh1XL-a-hxh-TJCyGl2yMAy6fMCUlGhlJ9qWyEI-_4fchyn6cjlFhOgkp1LyQq1mysaQUoStOkQ36nitCFY30lSRpm6kqVlaSTy77TuZEfo7_q-lAtQz4FKGn3f7On5XXJT3qrMvayXkGT7dnH9V3wr_eubNuP_v6X8AjnOv9g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1778962996</pqid></control><display><type>article</type><title>Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><source>PubMed Central</source><creator>Raja, M S A ; Saldana, M ; Goldsmith, C ; Burton, B J L</creator><creatorcontrib>Raja, M S A ; Saldana, M ; Goldsmith, C ; Burton, B J L</creatorcontrib><description>Intravitreal Ranibizumab (Lucentis) monotherapy is currently the standard of care for neovascular age-related macular degeneration (AMD), supported by well-conducted clinical trials and non-randomised studies. 1-4 Visual and anatomical outcomes are definitely better than Verteporfin Photodynamic therapy (PDT), but the treatment comes at a cost. 5 The current goal of anti-vascular endothelial growth factor (VEGF) agents is to stabilise and/or improve vision.</description><identifier>ISSN: 0007-1161</identifier><identifier>EISSN: 1468-2079</identifier><identifier>DOI: 10.1136/bjo.2009.174763</identifier><identifier>PMID: 20516142</identifier><identifier>CODEN: BJOPAL</identifier><language>eng</language><publisher>BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd</publisher><subject>Aged ; Aged, 80 and over ; Angiogenesis Inhibitors - therapeutic use ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Choroidal Neovascularization - drug therapy ; Choroidal Neovascularization - physiopathology ; degeneration ; Female ; Humans ; Macula ; Macular degeneration ; Macular Degeneration - drug therapy ; Macular Degeneration - physiopathology ; Male ; Medical imaging ; Middle Aged ; neovascular ; neovascularisation ; Ranibizumab ; treatment medical ; Treatment Outcome ; Vascular endothelial growth factor ; Visual Acuity</subject><ispartof>British journal of ophthalmology, 2010-11, Vol.94 (11), p.1543-1545</ispartof><rights>2010, Published by the BMJ Publishing Group Limited For permission to use, (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>Copyright: 2010 (c) 2010, Published by the BMJ Publishing Group Limited For permission to use, (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b397t-8db4d3740c33cc5303757047c57ea5d1c6e8fd447a53e5e63a992e32b91db3c43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://bjo.bmj.com/content/94/11/1543.2.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://bjo.bmj.com/content/94/11/1543.2.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3182,23551,27903,27904,77346,77377</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20516142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raja, M S A</creatorcontrib><creatorcontrib>Saldana, M</creatorcontrib><creatorcontrib>Goldsmith, C</creatorcontrib><creatorcontrib>Burton, B J L</creatorcontrib><title>Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes</title><title>British journal of ophthalmology</title><addtitle>Br J Ophthalmol</addtitle><description>Intravitreal Ranibizumab (Lucentis) monotherapy is currently the standard of care for neovascular age-related macular degeneration (AMD), supported by well-conducted clinical trials and non-randomised studies. 1-4 Visual and anatomical outcomes are definitely better than Verteporfin Photodynamic therapy (PDT), but the treatment comes at a cost. 5 The current goal of anti-vascular endothelial growth factor (VEGF) agents is to stabilise and/or improve vision.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Choroidal Neovascularization - drug therapy</subject><subject>Choroidal Neovascularization - physiopathology</subject><subject>degeneration</subject><subject>Female</subject><subject>Humans</subject><subject>Macula</subject><subject>Macular degeneration</subject><subject>Macular Degeneration - drug therapy</subject><subject>Macular Degeneration - physiopathology</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Middle Aged</subject><subject>neovascular</subject><subject>neovascularisation</subject><subject>Ranibizumab</subject><subject>treatment medical</subject><subject>Treatment Outcome</subject><subject>Vascular endothelial growth factor</subject><subject>Visual Acuity</subject><issn>0007-1161</issn><issn>1468-2079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkUtv1DAURiMEokNhzQ5ZYsFDyowfiR2zQ6NCkUZFQgUkNpbt3Jl6SOzBdlrKP-Hf4iqlCzasbF-f7_pxquopwUtCGF-ZfVhSjOWSiEZwdq9akIZ3NcVC3q8WGGNRE8LJUfUopX1ZUk7Ew-qI4rZUG7qofn_S3hn3axq1QTmCziP4jLYhIg_hUic7DToivYM6wqAz9GjUc62HHXiIOrvgkfPoUGYlm9CVyxdoF0KPjE4wOA_o0qVJD6gkXb5GLw3kDBHlC-0RXxH66g0itB6DL8EwZRtGSI-rB1s9JHhyOx5Xn9-dnK9P683H9x_Wbze1YVLkuutN0zPRYMuYtS3DTLQCN8K2AnTbE8uh2_ZNI3TLoAXOtJQUGDWS9IbZhh1XL-a-hxh-TJCyGl2yMAy6fMCUlGhlJ9qWyEI-_4fchyn6cjlFhOgkp1LyQq1mysaQUoStOkQ36nitCFY30lSRpm6kqVlaSTy77TuZEfo7_q-lAtQz4FKGn3f7On5XXJT3qrMvayXkGT7dnH9V3wr_eubNuP_v6X8AjnOv9g</recordid><startdate>201011</startdate><enddate>201011</enddate><creator>Raja, M S A</creator><creator>Saldana, M</creator><creator>Goldsmith, C</creator><creator>Burton, B J L</creator><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201011</creationdate><title>Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes</title><author>Raja, M S A ; Saldana, M ; Goldsmith, C ; Burton, B J L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b397t-8db4d3740c33cc5303757047c57ea5d1c6e8fd447a53e5e63a992e32b91db3c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Choroidal Neovascularization - drug therapy</topic><topic>Choroidal Neovascularization - physiopathology</topic><topic>degeneration</topic><topic>Female</topic><topic>Humans</topic><topic>Macula</topic><topic>Macular degeneration</topic><topic>Macular Degeneration - drug therapy</topic><topic>Macular Degeneration - physiopathology</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Middle Aged</topic><topic>neovascular</topic><topic>neovascularisation</topic><topic>Ranibizumab</topic><topic>treatment medical</topic><topic>Treatment Outcome</topic><topic>Vascular endothelial growth factor</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raja, M S A</creatorcontrib><creatorcontrib>Saldana, M</creatorcontrib><creatorcontrib>Goldsmith, C</creatorcontrib><creatorcontrib>Burton, B J L</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raja, M S A</au><au>Saldana, M</au><au>Goldsmith, C</au><au>Burton, B J L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes</atitle><jtitle>British journal of ophthalmology</jtitle><addtitle>Br J Ophthalmol</addtitle><date>2010-11</date><risdate>2010</risdate><volume>94</volume><issue>11</issue><spage>1543</spage><epage>1545</epage><pages>1543-1545</pages><issn>0007-1161</issn><eissn>1468-2079</eissn><coden>BJOPAL</coden><abstract>Intravitreal Ranibizumab (Lucentis) monotherapy is currently the standard of care for neovascular age-related macular degeneration (AMD), supported by well-conducted clinical trials and non-randomised studies. 1-4 Visual and anatomical outcomes are definitely better than Verteporfin Photodynamic therapy (PDT), but the treatment comes at a cost. 5 The current goal of anti-vascular endothelial growth factor (VEGF) agents is to stabilise and/or improve vision.</abstract><cop>BMA House, Tavistock Square, London, WC1H 9JR</cop><pub>BMJ Publishing Group Ltd</pub><pmid>20516142</pmid><doi>10.1136/bjo.2009.174763</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1161 |
| ispartof | British journal of ophthalmology, 2010-11, Vol.94 (11), p.1543-1545 |
| issn | 0007-1161 1468-2079 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_759875519 |
| source | MEDLINE; BMJ Journals - NESLi2; PubMed Central |
| subjects | Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Choroidal Neovascularization - drug therapy Choroidal Neovascularization - physiopathology degeneration Female Humans Macula Macular degeneration Macular Degeneration - drug therapy Macular Degeneration - physiopathology Male Medical imaging Middle Aged neovascular neovascularisation Ranibizumab treatment medical Treatment Outcome Vascular endothelial growth factor Visual Acuity |
| title | Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T08%3A18%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ranibizumab%20treatment%20for%20neovascular%20age-related%20macular%20degeneration%20in%20patients%20with%20good%20baseline%20visual%20acuity%20(better%20than%206/12):%2012-month%20outcomes&rft.jtitle=British%20journal%20of%20ophthalmology&rft.au=Raja,%20M%20S%20A&rft.date=2010-11&rft.volume=94&rft.issue=11&rft.spage=1543&rft.epage=1545&rft.pages=1543-1545&rft.issn=0007-1161&rft.eissn=1468-2079&rft.coden=BJOPAL&rft_id=info:doi/10.1136/bjo.2009.174763&rft_dat=%3Cproquest_cross%3E759875519%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1778962996&rft_id=info:pmid/20516142&rfr_iscdi=true |